Page last updated: 2024-09-03

imatinib mesylate and Alopecia

imatinib mesylate has been researched along with Alopecia in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bambara, HA; Lamien/Sanou, A; Ouédraogo Nde, NA; Ouédraogo, MS; Ouédraogo, NA; Tapsoba, GP; Thouraya Chtioui, A; Tiemtoré-Kambou, BM; Traoré, F; Zongo, N	1
Chen, SY; Cheng, ST; Yang, SY	1
Ergene, U; Ozbalci, D	1
Akin Belli, A; Ayer, M; Barut, SG; Dervis, E	1
de Leon, F; McBain, D; Petrlich, L; Pope, J; Seney, S; Summers, K; Vanderhoek, L; Watson, S	1

Trials

1 trial(s) available for imatinib mesylate and Alopecia

Article	Year
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis and rheumatism, 2011, Volume: 63, Issue:11 Topics: Adult; Aged; Alopecia; Anemia; Benzamides; Diarrhea; Double-Blind Method; Early Termination of Clinical Trials; Edema; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome	2011

Article

Year

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

Arthritis and rheumatism, 2011, Volume: 63, Issue:11

Topics: Adult; Aged; Alopecia; Anemia; Benzamides; Diarrhea; Double-Blind Method; Early Termination of Clinical Trials; Edema; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome

2011

Other Studies

4 other study(ies) available for imatinib mesylate and Alopecia

Article	Year
Breast and pleuropulmonary metastasis of multirecurrent scalp dermatofibrosarcoma protuberans: a case report. Journal of medical case reports, 2017, Apr-08, Volume: 11, Issue:1 Topics: Adult; Alopecia; Antigens, CD34; Antineoplastic Agents; Biopsy; Breast Neoplasms; Cough; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Recurrence, Local; Pleural Neoplasms; Prognosis; Scalp; Skin Neoplasms; Treatment Outcome	2017
Hair loss associated with imatinib treatment: a dermoscopic study. International journal of dermatology, 2017, Volume: 56, Issue:12 Topics: Alopecia; Antineoplastic Agents; Dermoscopy; Female; Humans; Imatinib Mesylate; Middle Aged; Scalp	2017
Successful management of imatinib despite alopecia and nail necrosis. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2013, Volume: 48, Issue:2 Topics: Alopecia; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Necrosis; Paronychia; Piperazines; Pyrimidines	2013
Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up. European journal of dermatology : EJD, 2016, Apr-01, Volume: 26, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Cheilitis; Cross-Sectional Studies; Drug Eruptions; Edema; Exanthema; Female; Follow-Up Studies; Humans; Hyperhidrosis; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pigmentation Disorders; Stomatitis, Aphthous; Time Factors; Young Adult	2016